In the future, alpesilib might be applied in more HER2-negative patients because its application (NCT02379247) demonstrated that in combination with nab-paclitaxel, a prolonged PFS could be achieved in heavily pre-treated patients with PIK3CA mutation in tumor or plasma compared to PIK3CA wildtype patients [273]. Here, PIK3CA is linked to neoplasm.